Results 81 to 90 of about 2,820 (114)

Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting. [PDF]

Rheumatol Ther
Arendse R, Rahman P, Baer P, Haaland D, Bessette L, Sholter D, Rachich M, Rampakakis E, Marrache AM, Lehman AJ, Asin-Milan O.   +10 more
europepmc   +1 more source

Interleukin-23 Inhibitors in Inflammatory Bowel Disease. [PDF]

BioDrugs
Puca P, Parello S, Colantuono S, Tursi A, Coppola G, Lopetuso LR, Scaldaferri F, Gasbarrini A, Papa A.   +8 more
europepmc   +1 more source

A 70-Year-Old Woman Receiving Immunosuppressive Therapy Presenting With Iliopsoas Abscess, Pulmonary Miliary Tuberculosis, and Secondary Hemophagocytic Lymphohistiocytosis. [PDF]

Am J Case Rep
Nakahara S, Kondo S, Capirig CJ, Shiraishi K, Nakamura M, Hamada O.   +5 more
europepmc   +1 more source

Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report. [PDF]

Clin Case Rep
Sahebari M, Karimoddini M, Tayyebi Meibodi N, Ataei Azimi S, Tafreshian S.   +4 more
europepmc   +1 more source

Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis. [PDF]

Intest Res
Moon JM.
europepmc   +1 more source

Influence of Pharmacokinetic-Pharmacodynamic Failure Mechanisms on Outcomes in Biologic Therapy Sequencing in Inflammatory Bowel Disease: A Retrospective Cohort Study. [PDF]

BioDrugs
Steenholdt C, Lorentsen RD, Henneberg J, Petersen PN, Brynskov J.   +4 more
europepmc   +1 more source

Treat-to-Target Monitoring Adherence and Rates of Healthcare Utilization in Patients With Inflammatory Bowel Disease in a Regional Healthcare System. [PDF]

Clin Transl Gastroenterol
Haydek JP, Mohan R, Lew J, Oonk A, Cheng D, Ahmed W, Click B, Fennimore B, Gerich M, Patel SG, Wani S, Hou JK, Scott FI.   +12 more
europepmc   +1 more source

Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database. [PDF]

PLoS One
Yang Y, Wang P, Li QX.
europepmc   +1 more source

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. [PDF]

Rheumatol Ther
Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF.   +13 more
europepmc   +1 more source